Dr Reddy's launches Bosutinib 400mg in US, secures exclusivity
Dr Reddy's Laboratories Ltd. announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, securing 180 days of exclusivity. The product, developed with MSN Laboratories, targets the Tyrosine Kinase Inhibitor category within oncology. The reference brand recorded U.S. sales of approximately $253.8 million for the 12 months ended April 2026.
*this image is generated using AI for illustrative purposes only.
Dr Reddy's Laboratories Ltd. announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States. This launch expands the company's oncology portfolio and secures 180 days of generic drug exclusivity for this strength in the U.S. market. The product addresses the Tyrosine Kinase Inhibitor category within oncology. The Bosulif brand recorded U.S. sales of approximately $253.8 million for the 12-month period ended April 2026, according to IQVIA National Sales Perspectives data.
Dr Reddy's collaborated with MSN Laboratories Private Limited for this product. Dr Reddy's holds the exclusive marketing rights in the United States, while MSN is responsible for the development and manufacturing. The collaboration leverages MSN Laboratories' manufacturing capabilities alongside Dr Reddy's marketing reach in the U.S., marking a significant addition to the company's complex oncology portfolio.
Product and Market Details
The following table outlines the key details of the launch:
| Detail: | Information |
|---|---|
| Product Name: | Bosutinib Tablets 400mg |
| Date of Launch: | June 13, 2026 |
| Product Category: | Oncology (Tyrosine Kinase Inhibitor) |
| Market: | United States |
| Exclusivity Period: | 180 days |
| Reference Brand Sales (12 months ended April 2026): | $253.8 million |
Leadership Commentary
Milan Kalawadia, CEO – North America, Dr Reddy's Laboratories, Inc., stated that the launch highlights the company's commitment to timely market entry for high-priority therapies. He emphasized the focus on strengthening the oncology portfolio and ensuring critical treatments remain accessible and affordable.
Bharat Reddy, Executive Director, MSN Laboratories, noted that the successful development and commercialization demonstrate the company's scientific, regulatory, and manufacturing capabilities in complex oncology products.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE089A01031/0b46eb3920564e3f.pdf
Historical Stock Returns for Dr Reddys Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.34% | -9.24% | -3.91% | +3.62% | -1.69% | +14.04% |
What revenue contribution does Dr Reddy's anticipate from the 180-day exclusivity period given the $253.8 million brand market size?
How will the pricing strategy for this generic impact the company's market share once additional competitors enter after the exclusivity window?
Does Dr Reddy's plan to pursue similar collaboration models with other manufacturers to expand its complex oncology portfolio?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
